SourceNeurobiology of Aging, 33, 9, (2012), pp. 1988-94
01 september 2012
Article / Letter to editor
Display more detailsDisplay less details
Primary and Community Care
Laboratory of Genetic, Endocrine and Metabolic Diseases
Neurobiology of Aging
SubjectDCN MP - Plasticity and memory; DCN NN - Brain networks and neuronal communication; NCEBP 7: Effective primary care and public health
Extracellular deposition of amyloid beta peptide (Abeta) has been implicated as a critical step in the pathogenesis of Alzheimer's disease (AD). In Down syndrome (DS), Alzheimer's disease is assumed to be caused by the triplication and overexpression of the gene for amyloid precursor protein (APP), located on chromosome 21. Plasma concentrations of Abeta1-40 and Abeta1-42 were determined in a population based study of 506 persons with DS, who were screened annually for dementia. We used Cox proportional hazards models to determine the risk of dementia. Demented persons with DS have a significantly higher plasma Abeta1-40 concentration than the nondemented (p = 0.05). Those with the highest concentrations of Abeta1-40 and Abeta1-42 have a higher risk to develop dementia. The risk to develop dementia during follow-up (mean 4.7 years) increased to 2.56 (95% confidence interval, 1.39-4.71) for Abeta1-42 and 2.16 (95% confidence interval, 1.14-4.10) for Abeta1-40. High plasma concentration of plasma Abeta1-40 and Abeta1-42 are determinants of the risk of dementia in persons with DS.
This item appears in the following Collection(s)
- Academic publications 
- Faculty of Medical Sciences 
Upload full text
Use your RU credentials (u/z-number and password) to log in with SURFconext to upload a file for processing by the repository team.